T1	Concept 37 46	monocytes
T2	Concept 51 62	macrophages
T3	Concept 92 100	cytokine
T5	Concept 163 173	SARS-CoV-2
T8	Concept 210 219	monocytes
T9	Concept 224 235	macrophages
T7	Concept 188 196	cytokine
T11	Action 197 204	release
T10	Concept 239 256	COVID-19 patients
R5	in-place Arg1:T5 Arg2:T10	
T6	Concept 365 369	load
T12	Concept 373 383	SARS-CoV-2
R10	has-property Arg1:T12 Arg2:T6	
T13	Concept 393 398	stage
R11	in-time Arg1:T12 Arg2:T13	
T15	Concept 479 484	tests
T16	Concept 438 444	assays
T17	Concept 528 543	CCoV strain A76
T18	Concept 555 580	recombinant S 103 protein
R14	has-property Arg1:T17 Arg2:T18	
T19	Concept 584 591	product
T20	Concept 650 660	SARS-CoV-2
T22	Concept 714 724	Human SARS
T24	Concept 798 817	potential evolution
T25	Action 844 854	appearance
T27	Concept 13 17	work
T28	Concept 4 12	previous
R18	has-property Arg1:T27 Arg2:T28	
T29	Action 18 31	demonstrating
R19	subject Arg1:T29 Arg2:T27	
T30	Action 67 74	produce
R1	target Arg1:T29 Arg2:T30	
R2	subject Arg1:T30 Arg2:T2	
R20	subject Arg1:T30 Arg2:T1	
T31	Concept 75 91	pro-inflammatory
R4	has-property Arg1:T3 Arg2:T31	
R21	target Arg1:T30 Arg2:T3	
T4	Concept 140 149	infection
T32	Concept 125 130	virus
T33	Concept 108 124	murine hepatitis
T34	Concept 131 139	strain-3
R22	causes Arg1:T32 Arg2:T33	
R23	has-property Arg1:T32 Arg2:T34	
R24	has-property Arg1:T32 Arg2:T4	
R25	in-time Arg1:T30 Arg2:T4	
T35	Action 257 261	need
T36	Concept 270 283	investigation
T37	Concept 262 269	further
R26	has-property Arg1:T36 Arg2:T37	
R3	target Arg1:T11 Arg2:T7	
R6	subject Arg1:T11 Arg2:T8	
R7	subject Arg1:T11 Arg2:T9	
T38	Action 179 187	triggers
R8	subject Arg1:T38 Arg2:T5	
R9	target Arg1:T38 Arg2:T11	
R27	subject Arg1:T35 Arg2:T38	
R28	target Arg1:T35 Arg2:T36	
T39	Action 304 312	progress
R29	subject Arg1:T39 Arg2:T36	
T40	Concept 320 328	hospital
R30	target Arg1:T39 Arg2:T40	
R31	in-place Arg1:T36 Arg2:T40	
T41	Concept 359 364	viral
T42	Concept 354 358	high
R32	has-property Arg1:T6 Arg2:T41	
R33	has-property Arg1:T6 Arg2:T42	
T43	Concept 387 392	early
R34	has-property Arg1:T13 Arg2:T43	
T44	Concept 413 418	onset
T45	Concept 405 412	symptom
R35	has-property Arg1:T45 Arg2:T44	
R36	in-context Arg1:T13 Arg2:T44	
T14	Concept 430 437	RT-LAMP
R12	is-a Arg1:T14 Arg2:T16	
T46	Concept 420 429	suggested
R13	has-property Arg1:T16 Arg2:T46	
T47	Action 458 464	usable
T48	Concept 469 478	screening
R37	subject Arg1:T47 Arg2:T16	
R38	has-property Arg1:T15 Arg2:T48	
R39	target Arg1:T47 Arg2:T15	
R40	in-context Arg1:T47 Arg2:T6	
R15	is-a Arg1:T18 Arg2:T19	
T49	Action 595 608	recombination
R41	has-property Arg1:T49 Arg2:T19	
T50	Concept 626 627	I
T51	Concept 632 634	II
T52	Concept 617 625	serotype
R42	is-a Arg1:T50 Arg2:T52	
T53	Concept 635 649	CCoV sequences
R43	has-property Arg1:T53 Arg2:T52	
R44	target Arg1:T49 Arg2:T53	
T21	Concept 678 685	segment
T54	Concept 667 677	disordered
R16	has-property Arg1:T21 Arg2:T54	
T55	Concept 691 707	168-289 residues
R45	in-place Arg1:T21 Arg2:T55	
R46	has-part Arg1:T20 Arg2:T21	
T23	Concept 763 770	segment
T56	Concept 750 762	unstructured
T57	Concept 776 792	145-289 residues
R17	has-part Arg1:T22 Arg2:T23	
R47	has-property Arg1:T23 Arg2:T56	
R48	in-place Arg1:T23 Arg2:T57	
T26	Concept 863 870	subtype
T58	Concept 858 862	mild
R49	has-property Arg1:T26 Arg2:T58	
T59	Concept 874 882	COVID-19
R50	subject Arg1:T25 Arg2:T26	
R51	in-context Arg1:T25 Arg2:T24	
R52	has-property Arg1:T59 Arg2:T26	
